Skip to main content

Altimmune Appoints Richard Eisenstadt as Chief Financial Officer

Written by Customer Service on . Posted in Public Companies.

GAITHERSBURG, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases, today announced the appointment of Richard Eisenstadt as Chief Financial Officer, effective December 31, 2021. Mr. Eisenstadt succeeds Will Brown, who is leaving Altimmune to pursue other opportunities.

“We are excited to welcome Rich to Altimmune and our executive management team. His extensive experience in financing and managing drug development and commercial operations will help ensure the company’s continued success,” said Vipin K. Garg Ph.D., President and Chief Executive Officer. “I’ve had the pleasure of working with Rich previously and this is an opportune time for him to join our team as we accelerate the clinical development of pemvidutide, a potential best-in-class treatment for obesity and NASH, and HepTcell, an exciting immunotherapeutic and a potential functional cure for chronic hepatitis B. I would like to thank Will for his contributions over the past years and wish him well in his future endeavors.”

Mr. Eisenstadt added, “I am delighted to join Altimmune and look forward to building on the accomplishments of the team. With the upcoming data readouts in 2022, there is substantial opportunity to grow and advance the company’s clinical pipeline and I am excited for the journey ahead.”

Mr. Eisenstadt is an accomplished executive with over 30 years of leadership experience in healthcare, life sciences, and emerging technology industries. He joins Altimmune from Aytu BioPharma, Inc., where he served as Chief Financial Officer following its merger with Neos Therapeutics, Inc. in March 2021. While Chief Financial Officer at Neos, he raised over $340 million in private and public equity and debt financings and supported the transition of the company from clinical stage to commercial operations. Prior to Neos, Mr. Eisenstadt served as Chief Financial Officer at Arborgen, Inc., and prior to that, Chief Financial Officer at Tranzyme, Inc., where he was instrumental in its initial public offering, negotiating several licensing agreements, and financing the company through late-stage clinical development. Mr. Eisenstadt received an M.B.A. from James Madison University and a B.A. in Economics from the University of North Carolina at Chapel Hill.

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Altimmune’s pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor & Media Contacts:

Vipin K. Garg, Ph.D.                                                        
President and Chief Executive Officer                                                 
Phone: 240-654-1450                                                        
vgarg@altimmune.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.